Cipla’s flagship product Sereflo gets nod from UK MHRA

23 Dec 2016 Evaluate

Cipla, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, has yielded a final approval for its lead MDI product Fluticasone + Salmeterol (Sereflo) from UK MHRA for its partner in the UK.

Sereflo, 25 mcg/125 mcg & 25 mcg/250 mcg are generic equivalent to GlaxoSmithKline’s Seretide Inhalers and are indicated for Asthma treatment. Seretide Inhaler, for the aforementioned strengths, had UK sales of approximately $278M for the 12 month period ending June 2016, as per IMS Health. Cipla’s Sereflo will be launched in the UK through a partner in the coming weeks.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1503.20 40.35 (2.76%)
05-Jun-2024 12:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1480.35
Dr. Reddys Lab 5831.75
Cipla 1503.20
Zydus Lifesciences 1058.70
Lupin 1615.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.